Table 1.
Characteristics of eligible studies.
| Study (Publication Year) | Country | Sample Size |
Mean Age |
Time to Onset(d) |
Affected Ear(R) |
Sex(F) |
With Tinnitus(n) |
With Vertigo(n) |
Initial PTA(dB) |
Diabetic population | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | T | C | T | C | T | C | T | C | T | C | T | C | |||
| [1]Chen, 2018 | China | 40 | 40 | 39.8 ± 2.4 | 39.9 ± 2.5 | NA | 19 | 19 | 19 | 20 | NA | NA | 69.4 ± 14.6 | 69.5 ± 14.7 | NA | |||
| [2]Gülce et al., 2017 | Turkey | 19 | 16 | 49.68 | 41.06 | 3.74 | 2.69 | NA | 7 | 5 | 18 | 13 | NA | NA | NA | |||
| [3]Hong et al., 2009 | Korea | 32 | 31 | 56.9 | 56.2 | NA | 14 | 13 | 19 | 20 | NA | 0 | 77.5 ± 27.6 | 79.9 ± 23.5 | NO | |||
| [4]Liang et al., 2012 | China | 60 | 50 | 21–79 | 17–78 | 8.5 | 7.5 | NA | 23 | 22 | NA | NA | 66.55 ± 16.52 | 66.2 ± 16.43 | NO | |||
| [5]Li Hui et al., 2013 | China | 38 | 38 | 45.3 ± 13.5 | 47.6 ± 15.2 | 6.34 ± 2.3 | 5.8 ± 3.5 | NA | 22 | 24 | 29 | 30 | 8 | 7 | 68.3 ± 23.5 | 63.2 ± 21.7 | NO | |
| [6]Lim, 2013 | Korea | 20 | 20 | 53.3 ± 15.3 | 51.3 ± 14.5 | 10.1 ± 8.1 | 5.4 ± 3.1 | 10 | 8 | 9 | 10 | NA | NA | 58.9 ± 31.2 | 57.8 ± 28.5 | did’t place limitation | ||
| [7]LI Zhi et al., 2015 | China | 32 | 32 | 45.2 ± 11.3 | 44.1 ± 10.5 | 4.9 ± 2.8 | 5.1 ± 1.9 | NA | 12 | 13 | NA | NA | 64.5 ± 20.1 | 65.8 ± 18.7 | NA | |||
| [8]Michael, 2018 | Greece | 34 | 35 | 53.2 ± 12.0 | 50.1 ± 17.3 | 4.6 ± 3.0 | 3.1 ± 3.0 | 20 | 18 | 16 | 15 | 31 | 32 | 13 | 16 | 81.4 ± 23.3 | 81.1 ± 28.8 | NO |
| [9]Peng et al., 2008 | China | 21 | 21 | 43.8 ± 13.4 | 42.1 ± 10.2 | 6.2 ± 2.4 | 5.2 ± 2.8 | NA | NA | NA | NA | 72.0 ± 18.6 | 69.0 ± 16.5 | NA | ||||
| 21 | 21 | 42.5 ± 11.6 | 45.2 ± 11.5 | 5.8 ± 3.5 | 5.7 ± 3.1 | NA | NA | NA | 71.0 ± 18.67 | 70.0 ± 17.6 | ||||||||
| [10]Qu et al., 2015 | China | 57 | 69 | 18–65 | 18–65 | ≤14 | ≤14 | NA | 25 | 33 | 31 | 33 | 12 | 13 | NA | did’t place limitation | ||
| [11]Tang et al., 2015 | China | 25 | 25 | 35.8 ± 9.0 | 34.2 ± 8.6 | 2.6 ± 1.3 | 2.5 ± 1.3 | 10 | 13 | 13 | 11 | 15 | 17 | 8 | 7 | 85.4 ± 5.6 | 84.8 ± 5.6 | YES |
| [12]Zhang et al., 2016 | China | 42 | 49 | 45.14 ± 13.56 | 45.22 ± 13.81 | 4.64 ± 3.63 | 4.98 ± 3.38 | 19 | 22 | 20 | 24 | 33 | 33 | 32 | 35 | 76.95 ± 15.49 | 78.08 ± 15.90 | did’t place limitation |
| [13]Rauch, 2011 | America | 129 | 121 | 51(19–85) | 52(18–80) | 7.0(6.4–7.6) | 6.7(6.1–7.4) | NA | 52 | 46 | 106 | 103 | 53 | 58 | 86.4(82.8–90.0) | 86.7(82.9–90.6) | NA | |
| [14]Kosyakov et al., 2011 | Tanzania | 24 | 25 | 49(35–52) | 40(32–53) | ≤30 | NA | 10 | 12 | NA | 4 | 6 | 41.0 ± 12.87 | 39.1 ± 16.97 | NO | |||
| [15]Dispenza et al., 2011 | Italy | 25 | 21 | 39–59 | 3–10 | 20 | 18 | 36 | 20 | 65 | 51 | NO | ||||||
T, Treatment group C, control group PTA, pure tone average NA, not available.